[Editorial] The evolving treatment landscape in Still’s disease

Although the treatment landscape in Still’s disease has seen substantial advances in recent decades, macrophage activation syndrome (MAS) continues to be one of the most feared—and unpredictable—complications of the disease. In June 2025, the US Food and Drug Administration (FDA) approved the first drug for MAS in Still’s disease marking a major milestone and offering long-awaited hope for patients.